[go: up one dir, main page]

GT200900126A - Novedosos anticuerpos antiproliferacion - Google Patents

Novedosos anticuerpos antiproliferacion

Info

Publication number
GT200900126A
GT200900126A GT200900126A GT200900126A GT200900126A GT 200900126 A GT200900126 A GT 200900126A GT 200900126 A GT200900126 A GT 200900126A GT 200900126 A GT200900126 A GT 200900126A GT 200900126 A GT200900126 A GT 200900126A
Authority
GT
Guatemala
Prior art keywords
new
antibodies
antibody
present
antiproliferation antibodies
Prior art date
Application number
GT200900126A
Other languages
English (en)
Inventor
Liliane Goetsch
Nathalie Corvaia
Jean Francois Haeuw
Cedric Bes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200900126A publication Critical patent/GT200900126A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCIÓN ESTÁ RELACIONADA CON ANTICUERPOS AISLADOS NOVEDOSOS, O LOS COMPUESTOS DERIVADOS O FRAGMENTOS FUNCIONALES DE LOS MISMOS, CAPACES DE INHIBIR LA PROLIFERACIÓN DE CÉLULAS TUMORALES IN VITRO Y/O IN VIVO, DICHOS ANTICUERPOS HAN SIDO OBTENIDOS POR TAMIZADO FUNCIONAL. MÁS PARTICULARMENTE, LA PRESENTE INVENCIÓN SE RELACIONA CON EL ANTICUERPO 6F4, ESPECÍFICO PARA LA PROTEÍNA JAM-A, COMO ASÍ TAMBIÉN CON SU USO PARA EL TRATAMIENTO DEL CÁNCER. TAMBIÉN ESTÁN CUBIERTAS LAS COMPOSICIONES FARMACÉUTICAS COMPUESTAS POR TALES ANTICUERPOS.
GT200900126A 2006-11-24 2009-05-14 Novedosos anticuerpos antiproliferacion GT200900126A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0610329A FR2909092B1 (fr) 2006-11-24 2006-11-24 Nouveaux anticorps anti-proliferation

Publications (1)

Publication Number Publication Date
GT200900126A true GT200900126A (es) 2011-09-02

Family

ID=37903981

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900126A GT200900126A (es) 2006-11-24 2009-05-14 Novedosos anticuerpos antiproliferacion

Country Status (27)

Country Link
US (2) US8071730B2 (es)
EP (1) EP2074148A1 (es)
JP (1) JP2010509931A (es)
KR (1) KR20090088878A (es)
CN (1) CN101535344B (es)
AU (1) AU2007324509B2 (es)
BR (1) BRPI0719323A2 (es)
CA (1) CA2670039A1 (es)
CL (1) CL2007003357A1 (es)
CR (1) CR10788A (es)
CU (1) CU23792A3 (es)
EC (1) ECSP099341A (es)
FR (1) FR2909092B1 (es)
GE (1) GEP20125629B (es)
GT (1) GT200900126A (es)
IL (1) IL198744A0 (es)
MA (1) MA30891B1 (es)
MX (1) MX2009005293A (es)
NI (1) NI200900079A (es)
NO (1) NO20092360L (es)
NZ (1) NZ576174A (es)
RU (1) RU2451689C2 (es)
SA (1) SA07280637B1 (es)
TN (1) TN2009000194A1 (es)
TW (1) TW200829602A (es)
UA (1) UA99602C2 (es)
WO (1) WO2008062063A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
WO2010002862A2 (en) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
US8802827B2 (en) * 2009-10-30 2014-08-12 Merck Sharp & Dohme Corp. AX1 PCSK9 antagonists
AU2011320314B2 (en) * 2010-10-29 2015-08-06 Immunogen, Inc. Novel EGFR-binding molecules and immunoconjugates thereof
EP2455403A1 (en) 2010-11-23 2012-05-23 Pierre Fabre Medicament Homogeneous humanized antibodies against JAM-A that inhibit proliferation
US20130287790A1 (en) * 2012-03-30 2013-10-31 The Board Of Trustees Of The Leland Standford Junior University Use of jam-a in diagnosing and treating leukemia
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
KR20150097304A (ko) 2014-02-18 2015-08-26 삼성전자주식회사 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체
MX2018010445A (es) * 2016-03-01 2019-10-17 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos especificos del receptor de poliovirus humano (rvp).
CA3029003A1 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
CA3032826A1 (en) * 2016-08-03 2018-02-08 Nextcure, Inc. Compositions and methods for modulating lair signal transduction
CN109022366A (zh) * 2018-08-16 2018-12-18 江南大学 一株分泌抗左旋咪唑单克隆抗体的杂交瘤细胞株及其应用
CN114740108B (zh) * 2022-03-28 2023-07-14 天津键凯科技有限公司 一种聚合物修饰抗体类药物的修饰度的测定方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20030171568A1 (en) * 1998-09-16 2003-09-11 Avi Ashkenazi Use of A33 antigens and JAM-IT
JP3998419B2 (ja) * 1998-04-03 2007-10-24 中外製薬株式会社 ヒト組織因子（ｔｆ）に対するヒト型化抗体およびヒト型化抗体の作製方法
CN1637019A (zh) * 1999-03-11 2005-07-13 Rmf迪克塔吉恩有限公司 血管粘着分子及其功能的调节
WO2005060457A2 (en) * 2003-12-04 2005-07-07 Pdl Biopharma, Inc. Treatment of inflammatory bowel diseases with anti-ip-10 antibodies
WO2006008076A2 (en) * 2004-07-16 2006-01-26 Universita Degli Studi Di Milano Methods and agents stimulating the immune response
EP1888639A1 (en) * 2005-05-12 2008-02-20 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-dsc2 antibody
AU2007243196A1 (en) * 2006-04-28 2007-11-08 Oregon Health & Science University Monoclonal antibodies specific for pancreatic endocrine, exocrine or ductal cell

Also Published As

Publication number Publication date
HK1132752A1 (en) 2010-03-05
RU2009123409A (ru) 2010-12-27
MX2009005293A (es) 2009-08-07
CA2670039A1 (en) 2008-05-29
EP2074148A1 (en) 2009-07-01
CN101535344B (zh) 2013-10-16
CR10788A (es) 2009-06-23
GEP20125629B (en) 2012-09-10
US8071730B2 (en) 2011-12-06
KR20090088878A (ko) 2009-08-20
TW200829602A (en) 2008-07-16
FR2909092B1 (fr) 2012-10-19
CL2007003357A1 (es) 2008-04-04
NI200900079A (es) 2010-11-10
UA99602C2 (ru) 2012-09-10
IL198744A0 (en) 2010-02-17
JP2010509931A (ja) 2010-04-02
BRPI0719323A2 (pt) 2014-02-04
CN101535344A (zh) 2009-09-16
SA07280637B1 (ar) 2012-04-11
NZ576174A (en) 2012-03-30
US20100092455A1 (en) 2010-04-15
FR2909092A1 (fr) 2008-05-30
WO2008062063A1 (en) 2008-05-29
ECSP099341A (es) 2009-06-30
US20120156191A1 (en) 2012-06-21
NO20092360L (no) 2009-08-11
AU2007324509A1 (en) 2008-05-29
AU2007324509B2 (en) 2013-01-17
RU2451689C2 (ru) 2012-05-27
TN2009000194A1 (en) 2010-10-18
MA30891B1 (fr) 2009-11-02
CU23792A3 (es) 2012-03-15

Similar Documents

Publication Publication Date Title
GT200900126A (es) Novedosos anticuerpos antiproliferacion
CL2008000670A1 (es) Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras.
EA201500261A1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
CL2007002593A1 (es) Compuestos derivados de 4-heteroaril-piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como rechazo de organos transplantados, sindromes autoinmunes y cancer.
CL2014000363A1 (es) Compuestos derivados de 1,2,5-oxadiazoles, inhibidores de indolamina 2,3-dioxigenasa; composicion farmaceutica; proceso para prepararlos; y su uso para el tratamiento de cancer, infeccion viral, depresion, desorden neurodegenerativo, trauma, cataratas, rechazo de transplante de un organo, enfermedades autoinmunes, entre otros.
GT201400057A (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
BR112012013664A2 (pt) rabdovírus oncolítico
MX2007014132A (es) Compuestos de diarilhidantoina.
GT200500237A (es) Derivados de pirimidina
GT200500260A (es) Amidas biciclicas como inhibidores de cinasa.
CL2008001632A1 (es) Compuestos derivados de acidos benzoilamino-indan-2-carboxilicos sustituidos, inhibidores del receptor cxcr5; composicion farmaceutica; y su uso en el tratamiento de efecciones fisiologicas inflamatorias, tales como artritis reumatoidea y asma.
MX2019013655A (es) Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.
BR112016012538A2 (pt) peptídeos citotóxicos e conjugados dos mesmos
CL2009001277A1 (es) Anticuerpo que enlaza especificamente el flt3 humano; fragmento de cualquiera de los anticuerpos antes dichos; acido polinucleico aislado; vector de expresion; celula recombinante; composicion farmaceutica y sus usos; producto que contiene el anticuerpo para tratar cancer
AR077333A1 (es) Anticuerpos humanos de alta afinidad para la angiopoyetina -2 humana
ECSP10010475A (es) Derivados de azetidina y ciclobutano como inhibidores de jak
HN2009000214A (es) Peptidomimeticos de smac utiles como inhibidores de proteinas de apoptosis (iap)
CL2007003774A1 (es) Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis.
MX2013001970A (es) Compuestos de pirrolopirimidina y usos de los mismos.
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
CL2007001711A1 (es) Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras.
CL2013001459A1 (es) Compuestos derivados de quinazolincarboxamida azetidina; proceso para prepararlos; composicion farmaceutica que los comprende; set (kit); y su uso para el tratamiento de enfermedades hiperproliferativas tales como cancer, inflamacion, pancreatitis o enfermedad renal, dolor, hiperplasia benigna de piel entre otras.
EA201390010A1 (ru) Замещенные триазолопиридины
BR112012014760A2 (pt) "composições orgânicas para tratar doenças relacionadas a hsf1, bem como seu uso"